Clinical Trials
16 trialsNCT03710876 2026-04-21
INFINITE
Ferring Ventures Limited
Phase 3 Completed
NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT06469138 2025-01-29
8479217
BerGenBio ASA
Phase 1 Completed
NCT04843007 2024-10-23
Alvopem® (Pemetrexed) Safety Assessment
NanoAlvand
Completed
NCT01265433 2024-10-09
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Sellas Life Sciences Group
Phase 2 Completed
NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT02709512 2023-10-04
ATOMIC
Polaris Group
Phase 2/3 Completed
NCT00738582 2022-09-22
Amatuximab
Morphotek
Phase 2 Completed
NCT02347917 2022-04-12
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
Sumitomo Pharma Co., Ltd.
Phase 1/2 Completed
NCT00700336 2021-07-20
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
CanBas Co. Ltd.
Phase 1/2 Completed
NCT01675765 2020-09-30
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Aduro Biotech, Inc.
Phase 1 Completed
NCT02357147 2020-03-17
ARTEMIS
Morphotek
Phase 2 Terminated
NCT01098266 2019-09-17
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
AGC Biologics S.p.A.
Phase 3 Completed
NCT03175172 2019-04-04
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Aduro Biotech, Inc.
Phase 2 Terminated
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed